S'abonner

Assessing the Caprini Score for Risk Assessment of Venous Thromboembolism in Hospitalized Medical Patients - 26/04/16

Doi : 10.1016/j.amjmed.2015.10.027 
Paul J. Grant, MD a, b, , M. Todd Greene, PhD, MPH a, b, Vineet Chopra, MD, MSc a, b, c, Steven J. Bernstein, MD, MPH a, b, c, Timothy P. Hofer, MD, MSc a, c, Scott A. Flanders, MD a, b
a Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Mich 
b Michigan Hospital Medicine Safety Consortium, Ann Arbor, Mich 
c Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, Mich 

Requests for reprints should be addressed to Paul J. Grant, MD, Department of Medicine, University of Michigan, 3119B Taubman Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109.Department of MedicineUniversity of Michigan3119B Taubman Center1500 E Medical Center DrAnn ArborMI48109

Abstract

Background

The optimal approach to assess risk of venous thromboembolism in hospitalized medical patients is unknown. We examined how well the Caprini risk assessment model predicts venous thromboembolism in hospitalized medical patients.

Methods

Between January 2011 and March 2014, venous thromboembolism events and risk factors were collected from non-intensive care unit medical patients hospitalized in facilities across Michigan. After calculation of the Caprini score for each patient, mixed logistic spline regression was used to determine the predicted probabilities of 90-day venous thromboembolism by receipt of pharmacologic prophylaxis across the Caprini risk continuum.

Results

A total of 670 (1.05%) of 63,548 eligible patients experienced a venous thromboembolism event within 90 days of hospital admission. The mean Caprini risk score was 4.94 (range, 0-28). Predictive modeling revealed a consistent linear increase in venous thromboembolism for Caprini scores between 1 and 10; estimates beyond a score of 10 were unstable. Receipt of pharmacologic prophylaxis resulted in a modest decrease in venous thromboembolism risk (odds ratio, 0.85; 95% confidence interval, 0.72-0.99; P = .04). However, the low overall incidence of venous thromboembolism led to large estimates of numbers needed to treat to prevent a single venous thromboembolism event. A Caprini cut-point demonstrating clear benefit of prophylaxis was not detected.

Conclusions

Although a linear association between the Caprini risk assessment model and the risk of venous thromboembolism was noted, an extremely low incidence of venous thromboembolism events in non-intensive care unit medical patients was observed. The Caprini risk assessment model was unable to identify a subset of medical patients who benefit from pharmacologic prophylaxis.

Le texte complet de cet article est disponible en PDF.

Keywords : Caprini risk assessment model, Deep venous thrombosis, Pharmacologic prophylaxis, Pulmonary embolism, Venous thromboembolism


Plan


 Funding: Blue Cross Blue Shield of Michigan and Blue Care Network supported data collection at each participating site and funded the data coordinating center but had no role in the study concept, interpretation of findings, or preparation, review, or final approval of the manuscript.
 Conflict of Interest: PJG reports receiving royalties from Wiley Publishing and compensation for expert witness testimony. SJB reports receiving compensation as a consultant for Blue Care Network and the Michigan Department of Community Health, honoraria for various talks, and grants from Blue Cross Blue Shield of Michigan, Michigan Health and Hospital Association, Department of Veterans Affairs, National Institutes of Health, and the Agency for Healthcare Research and Quality. TPH reports receiving grant funding as an investigator or co-investigator from the Department of Veterans Affairs, National Institutes of Health, and Agency for Healthcare Research and Quality. SAF reports receiving compensation for consultancies for the Institute for Healthcare Improvement and the Society of Hospital Medicine; royalties from Wiley Publishing; honoraria for various talks at hospitals as a visiting professor; grants from the Centers for Disease Control and Prevention Foundation, Blue Cross Blue Shield of Michigan, Michigan Health and Hospital Association, and Agency for Healthcare Research and Quality; and compensation for expert witness testimony.
 Authorship: All authors had access to the data and played a role in writing this manuscript.
 PJG and MTG contributed equally as lead authors.


© 2016  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 129 - N° 5

P. 528-535 - mai 2016 Retour au numéro
Article précédent Article précédent
  • Use of Targeted Temperature Management After Out-of-hospital Cardiac Arrest: A Meta-Analysis of Randomized Controlled Trials
  • Ahmed Mahmoud, Islam Y. Elgendy, Anthony A. Bavry
| Article suivant Article suivant
  • Dissecting the Dilemma: Uncontrolled Hypertension in a Pregnant Patient
  • Joyce Ji, J. Trevor Posenau, Kathryn J. Lindley, Alan C. Braverman

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.